March 4, 2013 - Atlanta, GA. The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection. Continue Reading...
Do you get our newsletter?
Sign up for our monthly Newsletter and get the latest info in you in box.
The 2013 WRI meeting focused on creating enduring engagement of women in HIV research and care across the research spectrum.
Get basic information about how disclosure can affect you, how to prepare to tell others, whom to tell, and relevant legal issues.
Jennifer Johnsen, MD, MPH, Managing Editor